UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Important health maintenance issues for children and adolescents with inflammatory bowel disease

Author
Paul A Rufo, MD, MMSc
Section Editor
Melvin B Heyman, MD, MPH
Deputy Editor
Alison G Hoppin, MD

INTRODUCTION

Inflammatory bowel disease (IBD) and associated medical or surgical interventions can have adverse effects on linear growth, pubertal development, and nutritional status. Patients with these diseases are also at risk for the development of complications in organs outside of the gastrointestinal tract, including the eye (iritis and uveitis), hepatobiliary tract (primary sclerosing cholangitis [PSC]), and skin (eg, erythema nodosum). Routine monitoring for these complications is mandatory. Finally, the immunosuppressive medications that are used to manage patients with IBD leave them at increased risk for the development of routine and opportunistic infections.

These risks require special health maintenance considerations, as discussed in this topic. Related issues in the diagnosis and management of IBD are discussed in separate topic reviews:

(See "Clinical presentation and diagnosis of inflammatory bowel disease in children".)

(See "Overview of the management of Crohn disease in children and adolescents".)

(See "Management of mild to moderate ulcerative colitis in children and adolescents".)

                       

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Nov 07 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Heuschkel R, Salvestrini C, Beattie RM, et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:839.
  2. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332:292.
  3. Verma S, Kirkwood B, Brown S, Giaffer MH. Oral nutritional supplementation is effective in the maintenance of remission in Crohn's disease. Dig Liver Dis 2000; 32:769.
  4. Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. J Pediatr Gastroenterol Nutr 2012; 55:93.
  5. DeFilippis EM, Sockolow R, Barfield E. Health Care Maintenance for the Pediatric Patient With Inflammatory Bowel Disease. Pediatrics 2016; 138.
  6. Gupta N, Lustig RH, Kohn MA, Vittinghoff E. Determination of bone age in pediatric patients with Crohn's disease should become part of routine care. Inflamm Bowel Dis 2013; 19:61.
  7. Kleinman RE, Baldassano RN, Caplan A, et al. Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology And Nutrition. J Pediatr Gastroenterol Nutr 2004; 39:15.
  8. Bousvaros A, Zurakowski D, Duggan C, et al. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. J Pediatr Gastroenterol Nutr 1998; 26:129.
  9. Alkhouri RH, Hashmi H, Baker RD, et al. Vitamin and mineral status in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 56:89.
  10. Battat R, Kopylov U, Szilagyi A, et al. Vitamin B12 deficiency in inflammatory bowel disease: prevalence, risk factors, evaluation, and management. Inflamm Bowel Dis 2014; 20:1120.
  11. Heyman MB, Garnett EA, Shaikh N, et al. Folate concentrations in pediatric patients with newly diagnosed inflammatory bowel disease. Am J Clin Nutr 2009; 89:545.
  12. Vagianos K, Bector S, McConnell J, Bernstein CN. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr 2007; 31:311.
  13. Wiskin AE, Fleming BJ, Wootton SA, Beattie RM. Anaemia and iron deficiency in children with inflammatory bowel disease. J Crohns Colitis 2012; 6:687.
  14. Herzog D, Bishop N, Glorieux F, Seidman EG. Interpretation of bone mineral density values in pediatric Crohn's disease. Inflamm Bowel Dis 1998; 4:261.
  15. Gokhale R, Favus MJ, Karrison T, et al. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998; 114:902.
  16. Pappa H, Thayu M, Sylvester F, et al. Skeletal health of children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 53:11.
  17. Pappa H. Vitamin D Deficiency and Supplementation in Patients with IBD. Gastroenterol Hepatol (N Y) 2014; 10:127.
  18. Aranow C. Vitamin D and the immune system. J Investig Med 2011; 59:881.
  19. Simpson DE, Dontu VS, Stephens SE, et al. Large variations occur in bone density measurements of children when using different software. Nucl Med Commun 2005; 26:483.
  20. Bachrach LK, Gordon CM, SECTION ON ENDOCRINOLOGY. Bone Densitometry in Children and Adolescents. Pediatrics 2016.
  21. Marini JC. Do bisphosphonates make children's bones better or brittle? N Engl J Med 2003; 349:423.
  22. Toussi SS, Pan N, Walters HM, Walsh TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis 2013; 57:1318.
  23. Ardura MI, Toussi SS, Siegel JD, et al. NASPGHAN Clinical Report: Surveillance, Diagnosis, and Prevention of Infectious Diseases in Pediatric Patients With Inflammatory Bowel Disease Receiving Tumor Necrosis Factor-α Inhibitors. J Pediatr Gastroenterol Nutr 2016; 63:130.
  24. American Acedemy of Pediatrics Clinical Report: Infectious complications with the use of biologic response modifiers in infants and children. http://pediatrics.aappublications.org/content/pediatrics/early/2016/07/14/peds.2016-1209.full.pdf (Accessed on July 19, 2016).
  25. Swaminath A, Bhadelia N, Wang YC. Cost-effectiveness of QuantiFERON testing before initiation of biological therapy in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19:2444.
  26. Wasan SK, Baker SE, Skolnik PR, Farraye FA. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol 2010; 105:1231.
  27. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.
  28. Lu Y, Bousvaros A. Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterol Hepatol (N Y) 2014; 10:355.
  29. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004; 10:677.
  30. Benchimol EI, Hawken S, Kwong JC, Wilson K. Safety and utilization of influenza immunization in children with inflammatory bowel disease. Pediatrics 2013; 131:e1811.
  31. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105:148.
  32. Lu Y, Bousvaros A. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr 2010; 50:562.
  33. Lu Y, Jacobson D, Bousvaros A. Immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15:1417.
  34. Siao D, Velayos F. Avoiding rash decision making: skin cancer screening of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2014; 12:274.
  35. Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12:210.
  36. Szigethy E, Levy-Warren A, Whitton S, et al. Depressive symptoms and inflammatory bowel disease in children and adolescents: a cross-sectional study. J Pediatr Gastroenterol Nutr 2004; 39:395.
  37. Clark JG, Srinath AI, Youk AO, et al. Predictors of depression in youth with Crohn disease. J Pediatr Gastroenterol Nutr 2014; 58:569.
  38. Rabbett H, Elbadri A, Thwaites R, et al. Quality of life in children with Crohn's disease. J Pediatr Gastroenterol Nutr 1996; 23:528.
  39. Mackner LM, Bickmeier RM, Crandall WV. Academic achievement, attendance, and school-related quality of life in pediatric inflammatory bowel disease. J Dev Behav Pediatr 2012; 33:106.
  40. Hummel TZ, Tak E, Maurice-Stam H, et al. Psychosocial developmental trajectory of adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2013; 57:219.
  41. Mackner LM, Greenley RN, Szigethy E, et al. Psychosocial issues in pediatric inflammatory bowel disease: report of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2013; 56:449.
  42. O'Donovan A. Inflammation and depression: unraveling the complex interplay in inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014; 58:541.
  43. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67:446.
  44. Szigethy EM, Youk AO, Benhayon D, et al. Depression subtypes in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014; 58:574.
  45. Pirinen T, Kolho KL, Simola P, et al. Parent and self-report of sleep-problems and daytime tiredness among adolescents with inflammatory bowel disease and their population-based controls. Sleep 2010; 33:1487.
  46. Benhayon D, Youk A, McCarthy FN, et al. Characterization of relations among sleep, inflammation, and psychiatric dysfunction in depressed youth with Crohn disease. J Pediatr Gastroenterol Nutr 2013; 57:335.
  47. van der Zaag-Loonen HJ, Grootenhuis MA, Last BF, Derkx HH. Coping strategies and quality of life of adolescents with inflammatory bowel disease. Qual Life Res 2004; 13:1011.
  48. Zimmerman LA, Srinath AI, Goyal A, et al. The overlap of functional abdominal pain in pediatric Crohn's disease. Inflamm Bowel Dis 2013; 19:826.
  49. Herzer M, Denson LA, Baldassano RN, Hommel KA. Patient and parent psychosocial factors associated with health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2011; 52:295.
  50. Kunz JH, Greenley RN, Howard M. Maternal, paternal, and family health-related quality of life in the context of pediatric inflammatory bowel disease. Qual Life Res 2011; 20:1197.
  51. Salazar G, Heyman MB. Benefits of attending a summer camp for children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014; 59:33.
  52. Leung Y, Heyman MB, Mahadevan U. Transitioning the adolescent inflammatory bowel disease patient: guidelines for the adult and pediatric gastroenterologist. Inflamm Bowel Dis 2011; 17:2169.
  53. Baldassano R, Ferry G, Griffiths A, et al. Transition of the patient with inflammatory bowel disease from pediatric to adult care: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2002; 34:245.
  54. Hait E, Arnold JH, Fishman LN. Educate, communicate, anticipate-practical recommendations for transitioning adolescents with IBD to adult health care. Inflamm Bowel Dis 2006; 12:70.
  55. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138:738.
  56. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51:660.
  57. Levin B. Inflammatory bowel disease: role of endoscopic surveillance. Clinical Update 2000; 7:1.
  58. Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med 2015; 372:1441.
  59. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012; 143:390.
  60. Ashworth LA, Billett A, Mitchell P, et al. Lymphoma risk in children and young adults with inflammatory bowel disease: analysis of a large single-center cohort. Inflamm Bowel Dis 2012; 18:838.